DOD Duchenne Muscular Dystrophy, Idea Development Award
ID: 358801Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358801
Timeline
    Description

    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA), is offering the Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) for fiscal year 2025. This grant aims to support innovative, high-risk research that seeks to improve outcomes for individuals with Duchenne muscular dystrophy (DMD), encouraging applications that present well-formulated hypotheses based on solid scientific rationale. The program is particularly focused on studies targeting the primary pathology of DMD and emphasizes collaboration among experienced researchers, while excluding clinical trials in favor of fundamental and preparatory research. The total funding available is approximately $1.68 million, with up to three awards capped at $350,000 each for direct costs over a maximum of two years. Interested applicants must submit a pre-application by July 2025, followed by a full application by August 2025, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942525DMDRPIDA_GG.pdf
    The Department of Defense’s Duchenne Muscular Dystrophy Research Program (DMDRP) is offering the Idea Development Award (IDA) for FY25 to support innovative, high-risk research that aims to improve outcomes for individuals with Duchenne muscular dystrophy (DMD). The program encourages applications with well-formulated hypotheses grounded in solid scientific rationale, particularly from early-career and transitioning investigators. The funding total is approximately $1.68 million, allowing up to three awards with a cap of $350,000 for direct costs over a maximum of two years. Applications are due in July and August 2025, with a two-step submission process involving a pre-application and a full application. Eligibility extends to a wide range of organizations, including academic institutions and for-profit entities, while emphasizing collaboration among experienced researchers. The program specifically seeks studies targeting the primary pathology of DMD, particularly innovative therapeutic strategies. The award mechanism excludes clinical trials, focusing instead on fundamental and preparatory research. The application review process consists of peer and programmatic evaluations based on innovation, impact, research strategy, feasibility, personnel qualifications, and environmental considerations. This initiative underlines the U.S. Army's commitment to advancing DMD research for both military families and the public.
    Similar Opportunities
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome, aimed at enhancing health and quality of life for individuals with Down syndrome. This funding opportunity invites researchers to propose innovative exploratory and developmental projects that address critical needs identified in the INCLUDE Project objectives, potentially leading to breakthroughs in biomedical, behavioral, or clinical research. The total estimated program funding is $1 million, with individual awards ranging from $50,000 to $200,000, and the application process is open to a diverse range of eligible applicants, including tribal governments and community-based organizations. Interested parties should contact Dr. Melissa Parisi at 301-728-1861 or via email at parisima@mail.nih.gov for further information, with applications due by February 19, 2026, and awards expected to be announced by September 1, 2026.
    INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE Project: Transformative Research Awards for Down syndrome, aimed at advancing innovative research to improve health and quality of life for individuals with Down syndrome. This funding opportunity invites applications for groundbreaking research that can establish new scientific paradigms or develop transformative technologies related to Down syndrome and its co-occurring conditions, with no preliminary data required. The program has an estimated total funding of $3 million, with individual awards ranging from $250,000 to $500,000, and is expected to support approximately four projects. Interested applicants can reach out to Dr. Charlene Schramm at schrammc@nih.gov or by phone at 301-402-3793, with applications due by February 19, 2026, and anticipated awards announced by September 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Intellectual and Developmental Disabilities Research Centers 2025 (P50 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the Intellectual and Developmental Disabilities Research Centers (IDDRCs) in 2025, with a focus on advancing research related to intellectual and developmental disabilities (IDD). This initiative aims to foster collaborative research efforts that enhance the diagnosis, prevention, treatment, and amelioration of IDD through specialized multi-project grant awards under the P50 activity code. The estimated total program funding is $18 million, with approximately 12 awards expected, and interested applicants are encouraged to prepare their proposals ahead of the anticipated application solicitation, which is expected to open after the synopsis is posted on July 25, 2025, and close on October 15, 2025. For further inquiries, potential applicants can contact Dr. Melissa A. Parisi at 301-435-6880 or via email at parisima@mail.nih.gov.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the INCLUDE Project, specifically for Clinical Trials Phased Awards aimed at advancing research on Down syndrome. This grant program encourages Exploratory/Developmental Phased Innovation (R61/R33) applications to develop clinical trials addressing critical health conditions associated with Down syndrome, with a focus on milestone-driven research. The total funding available for this initiative is approximately $3 million, with an expected four awards, and applications may request a minimum of $100,000. Interested applicants should note that the project period can extend up to five years, with the R61 phase supporting preliminary studies for up to two years, followed by a potential R33 phase for clinical trial support. For further inquiries, applicants can contact Laurie Ryan, PhD, at 301-496-9350 or via email at ryanl@nih.gov. The application deadline is set for February 19, 2026, with awards anticipated to be announced by September 1, 2026.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Intellectual and Developmental Disabilities Research Centers 2025 (P50 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Intellectual and Developmental Disabilities Research Centers (IDDRCs) in 2025, with a focus on advancing research in the diagnosis, prevention, treatment, and amelioration of intellectual and developmental disabilities (IDD). This initiative aims to foster collaborative research through specialized centers supported by multi-project grant awards under the P50 activity code. The anticipated funding amount for each center is up to $1 million, with the NOFO expected to be published in Summer 2024 and applications due in Fall 2024. Interested applicants should prepare to develop meaningful collaborations and responsive projects, as the estimated award date is set for July 1, 2025.
    US Army Combat Capabilities Development Command (DEVCOM) Indo-Pacific Fundamental Research Collaboration Opportunities
    USAF 347 Contracting Squadron
    The USAF 347 Contracting Squadron is offering a federal grant opportunity titled "US Army Combat Capabilities Development Command (DEVCOM) Indo-Pacific Fundamental Research Collaboration Opportunities." This initiative aims to foster the discovery, development, and integration of novel science and technologies specifically within the Indo-Pacific region, explicitly excluding engagements in the Continental United States. The funding, categorized under Science and Technology and other Research and Development, has an award ceiling of $9.5 million and a floor of $10,000, with an expected 51 awards to be made. Interested applicants can reach out to Mr. Kazuhito Urano or Mr. Joshua B. Grubb for further inquiries, and proposals must be submitted by August 30, 2027, as detailed on the System for Award Management (SAM) website.